Sort
82,697 grants matching “vaccine development”
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Timothy Rodell · Globeimmune, Inc. · R01 · FY2015 · AI
Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection
$1,000,000Yanming Du · Harlingene Life Sciences Llc · R42 · FY2025 · AI
Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine.
$1,000,000Nhi Khuong · Lumen Bioscience, Inc. · R42 · FY2023 · AI
An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC
$1,000,000Timothy R Fouts · Profectus Biosciences, Inc. · R44 · FY2015 · AI
Plasmodium vivax recombinant CS protein vaccine for malaria
$1,000,000B. Kim Lee Sim · Protein Potential, Llc · R44 · FY2010 · AI
A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine
$1,000,000Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2016 · AI
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
$1,000,000Glen Andrew Coburn · Venatorx Pharmaceuticals, Inc. · R44 · FY2023 · AI
Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease.
$1,000,000Jay Evans · University Of Montana · N01 · FY2022 · AI
Non-Human Primate Lymphoid Organ Chips for Vaccine Assessment
$1,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2024 · AI
Development of an E6 based Rapid Strip Test Commercial Prototype for Cervical Can
$1,000,000Johannes G Schweizer · Arbor Vita Corporation · R44 · FY2009 · AI
International Training in AIDS-Related Epidemiology
$1,000,000Harvard University (Sch Of Public Hlth) · D43 · FY2003 · TW
HIV-1/SIV Antibody Neutralization Assay Improvements and Database Development
$1,000,000Christos J Petropoulos · Monogram Biosciences, Inc. · R44 · FY2008 · AI
Recombinant antigen diagnostics for filoviruses
$1,000,000Matthew L Boisen · Zalgen Labs, Llc · R44 · FY2016 · AI
Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.
$1,000,000Christopher H Clegg · Tria Bioscience Corporation · R44 · FY2013 · AI
HIV Research for Prevention Conference combining AIDS Vaccine & Microbicides
$1,000,000Eric Hunter · Emory University · R13 · FY2014 · AI
Development of VLP vaccine for RSV
$1,000,000Jorge C Blanco · Sigmovir Biosystems, Inc. · R44 · FY2019 · AI
Recombinant yeast vaccines for sensitive and drug-resistant M. tuberculosis
$1,000,000Richard Chatterton Duke · Globeimmune, Inc. · R01 · FY2016 · AI
Respiratory Virus Vaccine and Adjuvant Exploration
$1,000,000Ralph S Baric · Univ Of North Carolina Chapel Hill · U01 · FY2023 · AI
Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques
$1,000,000Yvonne J Rosenberg · Plantvax, Inc. · R44 · FY2016 · AI
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2012 · AI
Technology for Culture of Megathura crenulata for KLH
$1,000,000Stellar Biotechnologies, Inc. · R44 · FY2005 · CA
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2022 · AI
Delivery system development for a reservoir targeted Lyme disease vaccine
$1,000,000Linden T Hu · Foodsource Lure Corporation · R42 · FY2012 · AI
MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial
$1,000,000Laurel A. Lagenaur · Osel, Inc. · R44 · FY2020 · AI
Oral, replicating Ad4-HIV vaccine development & evaluation in NHP challenge model
$1,000,000Marc Joseph Gurwith · Paxvax, Inc. · R44 · FY2013 · AI